SLAS Discovery Guest Editors Martin Main, Ph.D. (Medicines Discovery Catapult) and Andrew Zhang, Ph.D. (AstraZeneca) invite the submission of abstracts on advances in cellular compound-target engagement measurement and application to target deconvolution in drug discovery for publication in a 2020 special issue. Manuscript proposals (abstracts) will be used to select and invite papers for review and publication consideration.
Drs. Main and Zhang seek high-quality, short or full-length research reports, reviews and perspectives related to all methods for monitoring compound-target engagement in cells and for deconvoluting the molecular target of biologically active compounds. Manuscript proposals (abstracts) are welcome from academia, industry and vendors. Areas of particular interest include but are not limited to:
Submit your manuscript proposal before March 1, 2019.
Invited authors will be notified by March 8, 2019. Invited manuscripts will need to be completed and submitted by July 1, 2019. All submitted papers will be subject to peer-review to ensure scientific rigor, clarity of expression and integration with other contributions in the SLAS Technology special issue. Submissions from SLAS members, nonmembers and especially IEEE NANOMED 2018 speakers are welcome. No APCs.
Publication note: After submissions are accepted, they typically publish online ahead-of-print within 30 days and become immediately searchable and citeable with a DOI.
Questions? Please e-mail email@example.com or call +1.630.256.7527, ext. 105.